Edition:
United Kingdom

Orphazyme Prepares To File Arimoclomol In US For Niemann-Pick Disease Type C


Monday, 22 Jul 2019 

July 22 (Reuters) - Orphazyme A/S ::SAID ON SUNDAY PREPARES FOR FILING OF ARIMOCLOMOL IN US FOR NIEMANN-PICK DISEASE TYPE C (NPC).HAD POSITIVE MEETING WITH FDA AND REMAINS ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR ARIMOCLOMOL FOR NPC IN H1 2020.PLANS TO INTRODUCE AN EARLY ACCESS PROGRAM FOR NPC IN THE FALL OF 2019. 

Company Quote

63.2
 --
16 Aug 2019